Trials / Recruiting
RecruitingNCT05908695
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
A 36-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,312 (estimated)
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GV-971 | Administered PO |
| DRUG | Placebo | Administered PO |
Timeline
- Start date
- 2023-08-31
- Primary completion
- 2029-06-01
- Completion
- 2029-12-01
- First posted
- 2023-06-18
- Last updated
- 2023-11-09
Locations
50 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05908695. Inclusion in this directory is not an endorsement.